Last reviewed · How we verify
NCT05186233: SHIFT
Use of Consumer Sleep Technology to Treat Shift Work Disorder
NA trial testing Phototherapy in Shift-work Disorder in 63 participants. Completed in 31 March 2025.
31 March 2025
Quick facts
| Lead sponsor | Henry Ford Health System |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 63 |
| Start date | 18 April 2022 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Phototherapy
Conditions studied
- Shift-work Disorder — all drugs for Shift-work Disorder →
Sponsor
Henry Ford Health System — full company profile →
Who can join
18 and older, any sex, with Shift-work Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the effectiveness of a personalized light exposure schedule for Shift Work Disorder (SWD) in night shift workers compared to a non-personalized light exposure schedule.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05186233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Phototherapy
Trials testing the same drug.
- NCT07488195 — A Study Of Phototherapy In Patients With Dementia To Improve BPSD · NA · not yet recruiting
- NCT07150494 — Predictive and Diagnostic Value of BIND Score in Assessment of Severe Neonatal Jaundice Cases in Neonatal Intensive Care · not yet recruiting
- NCT07110987 — The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect H · NA · recruiting
- NCT06235281 — Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) · EARLY_PHASE1 · suspended
- NCT06960161 — Exploring the Use of Phototherapy to Improve CPAP Compliance · Phase 1 · recruiting
Other recruiting trials for Shift-work Disorder
Currently open trials in the same condition.
- NCT06492109 — The Peripheral Blood Multi-Omics Study on Sleep Loss · NA · recruiting
- NCT06440434 — Effects of Morningness on Night Split Shift Performance · NA · active not recruiting
- NCT06288568 — Night Shift Work and Biomarkers of Obesity Risk in Hospital and Industry Workers · recruiting
- NCT05424406 — Role of Sleep Reactivity in Shift Work Disorder · NA · recruiting
- NCT05633498 — Self-help Book for Shift Work Related Problems · NA · recruiting
Other Henry Ford Health System trials
Trials by the same sponsor.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
- NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
- NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
- NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05186233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing